Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.43 |
| ▸ | PDE4A | P27815 | 6/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034711 | 0.88 | TSHR (0.49) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7416624 | 0.82 | PDE4B (0.54) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14340984 | 0.81 | RORC (0.64) | KMT2AMEN1RORCALDH1A1LMNA | |
| SCHEMBL7420388 | 0.81 | PDE4B (0.46) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL26451878 | 0.81 | PDE4B (0.53) | KMT2APDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17059928 | 0.80 | CREBBP (0.63) | CREBBPKMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL14003536 | 0.79 | PDE4B (0.61) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL27806919 | 0.79 | PDE4D (0.47) | PDE4DPDE4BPDE4APDE4CMAPK14 | |
| SCHEMBL4170146 | 0.78 | KMT2A (0.57) | CREBBPKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL26030947 | 0.77 | RORC (0.43) | CREBBPKMT2AMEN1RORCPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | CREBBP 1243/4885KMT2A 3265/4885MEN1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.